NOVAVAX INC Cash and Cash Equivalents
NOVAVAX INC (NVAX) had Cash and Cash Equivalents of $191.46 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-06
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $191.46M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $228.36M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $240.63M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $268.02M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $191.46M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $228.36M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $240.63M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $268.02M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $253.74M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $263.34M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $530.23M 10-K · filed 2026-02-26 |
| 2024-09-30 | $573.63M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $680.16M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $480.59M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $568.50M 10-K · filed 2026-02-26 |
| 2023-09-30 | $651.10M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $505.91M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $624.95M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $1.34B 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.28B 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.38B 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.57B 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.52B 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.94B 10-Q · filed 2021-11-05 |
| 2021-06-30 | $2.07B 10-Q · filed 2021-08-05 |
| 2021-03-31 | $2.00B 10-Q · filed 2021-05-10 |
| 2020-12-31 | $553.40M 10-K · filed 2023-02-28 |
| 2020-09-30 | $334.17M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $424.39M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $179.88M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $78.82M 10-K · filed 2021-03-01 |
| 2019-09-30 | $71.17M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $72.00M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $97.71M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $70.15M 10-K · filed 2020-03-11 |
| 2018-09-30 | $56.50M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $88.47M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $113.40M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $106.31M 10-K · filed 2019-03-18 |
| 2017-09-30 | $104.25M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $75.79M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $95.85M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $144.35M 10-K · filed 2018-03-14 |
| 2016-09-30 | $119.95M 10-Q · filed 2017-11-07 |
| 2016-06-30 | $89.39M 10-Q · filed 2017-08-08 |
| 2016-03-31 | $132.22M 10-Q · filed 2017-05-08 |
| 2015-12-31 | $93.11M 10-K · filed 2018-03-14 |
| 2015-09-30 | $138.14M 10-Q · filed 2016-11-09 |
| 2015-06-30 | $167.38M 10-Q · filed 2016-08-09 |
| 2015-03-31 | $215.05M 10-Q · filed 2016-05-05 |
| 2014-12-31 | $32.34M 10-K · filed 2018-03-14 |
| 2014-09-30 | $34.47M 10-Q · filed 2015-11-09 |
| 2014-06-30 | $103.86M 10-Q · filed 2015-08-10 |
| 2014-03-31 | $109.92M 10-Q · filed 2015-05-07 |
| 2013-12-31 | $119.47M 10-K · filed 2017-02-27 |
| 2013-09-30 | $122.49M 10-Q · filed 2014-11-06 |
| 2013-06-30 | $2.57M 10-Q · filed 2014-08-07 |
| 2013-03-31 | $9.02M 10-Q · filed 2014-05-08 |
| 2012-12-31 | $17.40M 10-K · filed 2016-02-29 |
| 2012-09-30 | $10.74M 10-Q · filed 2013-11-12 |
| 2012-06-30 | $15.33M 10-Q · filed 2013-08-08 |
| 2012-03-31 | $13.87M 10-Q · filed 2013-05-09 |
| 2011-12-31 | $14.10M 10-K · filed 2015-02-27 |
| 2011-09-30 | $14.32M 10-Q · filed 2012-11-09 |
| 2011-06-30 | $13.09M 10-Q · filed 2012-08-09 |
| 2011-03-31 | $8.36M 10-Q · filed 2012-05-09 |
| 2010-12-31 | $8.06M 10-K · filed 2014-03-12 |
| 2010-09-30 | $16.21M 10-Q · filed 2011-11-08 |
| 2010-06-30 | $9.45M 10-Q · filed 2011-08-09 |
| 2009-12-31 | $38.76M 10-K · filed 2013-03-12 |
| 2008-12-31 | $26.94M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |